<DOC>
	<DOCNO>NCT00638794</DOCNO>
	<brief_summary>Prospective , multicenter , registry least 11,000 ( 15,000 ) consecutive patient coronary artery disease undergo stent-assisted percutaneous coronary intervention ( PCI ) use DES without major procedural complication .</brief_summary>
	<brief_title>Assessment Dual AntiPlatelet Therapy With Drug Eluting Stents</brief_title>
	<detailed_description>To determine : 1. frequency , time correlate ( clinical angiographic ) drug-eluting stent ( DES ) thrombosis patient population clinical angiographic exclusion criterion , 2. relationship aspirin and/or clopidogrel hyporesponsiveness , general platelet reactivity early late DES thrombosis separate phase stratify whether patient take dual ( aspirin plus clopidogrel ) single ( aspirin alone ) antiplatelet therapy , 3. combine finding 2 objective , identify cohort represent significant proportion patient increase risk early and/or late DES stent thrombosis .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Patients undergo PCI least one DES implant PCI treat lesion successful ( diameter stenosis &lt; 30 % TIMI 3 flow treat lesion ) without major complication ( define freedom procedural death , intraprocedural stent thrombosis , procedural myocardial infarction sustain vessel closure , need emergency bypass graft surgery ) . One bare metal stent ( BMS ) may implant , lesion may treat without stenting long least one DES implant . However , procedure must successful uncomplicated ( define ) lesion ( DES + BMS + nonstent ) . 2 . Aspirin use : Adequate aspirin load give prior PCI : least 300 mg non enteric coat oral aspirin least 1 hour prior procedure 324 mg chew 250 mg IV aspirin least 30 minute prior procedure . 3 . Patient Hematocrit 30 52 % Platelet Count great 100,000/Âµl . 4 . For US site : Only FDAapproved DES stent may use study . For OUS site : Only DES stent CE mark approval may use study . 5 . PCI perform unfractionated low molecular weight heparin , bivalirudin procedural antithrombin . 6 . Patient guardian able provide inform write consent . 1 . Patients blood Accumetrics VerifyNow platelet function test draw minimum clopidogrel load duration Glycoprotein ( GP ) IIb/IIIa inhibitor washout duration follow : 1 . Clopidogrel loading : Clopidogrel load pre PCI recommend , post PCI clopidogrel load acceptable per standard care . In patient ( whether clopidogrel initiate pre post PCI ) , prior blood draw VerifyNow platelet function testing , 600 mg load dose must give least 6 hour prior , 300 mg load dose must give least 12 hour prior , patient must maintain least 75 mg clopidogrel daily least 5 day . 2 . GP IIb/IIIa inhibitor washout : Eptifibatide tirofiban must discontinue least 24 hour prior VerifyNow platelet function test . Abciximab must discontinue 10 day prior VerifyNow platelet function test . 2 . Inability VerifyNow system measure either Aspirin , P2Y12 IIb/IIIa platelet responsiveness . 3 . Severe allergy stainless steel , contrast dye , antithrombin agent ( unfractionated low molecular weight heparin bivalirudin ) , aspirin clopidogrel adequately premedicated . 4 . Concurrent enrollment another trial involve investigational stent , antithrombotic antiplatelet agent . Patient investigational trial reach primary endpoint may enrol ADAPTDES long trial involve investigational stent , antithrombotic antiplatelet agent inclusion patient effect endpoint either study . 5 . Patients bypass graft surgery plan within 2 year . 6 . Patients stent thrombosis performance predischarge VerifyNow platelet function test . 7 . Patients unwilling unable complete clinical followup duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Myocardial Ischemia</keyword>
</DOC>